Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy?

Area of Science:

• Cardiology
• Hypertension Research
• Pharmacology

Background:

• Left ventricular hypertrophy (LVH) is a critical risk factor for cardiovascular morbidity and mortality.
• Arterial hypertension is a primary cause of LVH, with the renin-angiotensin-aldosterone system playing a key pathophysiological role.
• Nonpharmacologic treatments can be effective for LVH in mild essential hypertension.

Purpose of the Study:

• To evaluate the efficacy of different antihypertensive drug classes in reversing left ventricular hypertrophy.
• To compare the effectiveness of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) against beta-blockers in LVH regression.
• To determine if LVH regression is associated with improved cardiovascular outcomes.

Main Methods:

• Analysis of multiple meta-analyses involving several thousand patients.
• Review of large-scale prospective trials, including the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
• Comparison of treatment effects on LVH reversal across different antihypertensive drug categories.

Main Results:

• Meta-analyses consistently show ACEIs and ARBs achieve significantly better LVH reversal than beta-blockers.
• The LIFE study confirmed the superiority of ARBs over beta-blockers in a large prospective trial.
• LVH regression was demonstrated to be associated with better cardiovascular outcomes for the first time.

Conclusions:

• Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are superior to beta-blockers for reversing left ventricular hypertrophy.
• Regression of left ventricular hypertrophy is linked to improved cardiovascular prognosis.
• Pharmacological treatment targeting the renin-angiotensin-aldosterone system is crucial for managing LVH.